All subjects were heterozygous FH, and the majority of subjects had an LDLR genetic variant; furthermore, more subjects were on rosuvastatin 20 mg than atorvastatin 40 mg and 39.3% of subjects were on antihypertensive therapy. Here, LDLR is linked to familial hyperaldosteronism.